Bank of New York Mellon Corp Purchases 1,389 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Bank of New York Mellon Corp boosted its position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 11.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 13,896 shares of the company’s stock after purchasing an additional 1,389 shares during the period. Bank of New York Mellon Corp’s holdings in Gyre Therapeutics were worth $168,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Barclays PLC lifted its holdings in shares of Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the period. Geode Capital Management LLC raised its position in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares in the last quarter. State Street Corp raised its position in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares in the last quarter. FMR LLC bought a new stake in Gyre Therapeutics during the third quarter worth $47,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares in the last quarter. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Trading Up 0.2 %

Shares of NASDAQ GYRE opened at $9.11 on Friday. The company has a market cap of $852.81 million, a price-to-earnings ratio of 182.20 and a beta of 1.93. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $19.00. The stock has a 50-day moving average price of $11.16 and a two-hundred day moving average price of $12.08.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings data on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. The company had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million.

Analyst Ratings Changes

Separately, Noble Financial started coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating for the company.

Gyre Therapeutics Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.